Publicacións nas que colabora con Manuel Barreiro de Acosta (15)

2023

  1. Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP

    Journal of Clinical Medicine, Vol. 12, Núm. 14

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  3. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU

    Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058

  4. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Comparison of original and biosimilar infliximab (CTP-13) in biologic-naïve patients with Crohn’s disease and ulcerative colitis: a retrospective, multicenter real-life study in Spain

    Revista Española de Enfermedades Digestivas, Vol. 113, Núm. 3, pp. 170-178

2016

  1. Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent

    Digestive and Liver Disease, Vol. 48, Núm. 6, pp. 613-619

  2. Tuberculosis in anti-tumour necrosis factortreated inflammatory bowel disease patients after the implementation of preventive measures: Compliance with recommendations and safety of retreatment

    Journal of Crohn's and Colitis, Vol. 10, Núm. 10

2014

  1. Drug trough levels and primary nonresponse to antiTNF therapy in moderate-severe Crohn disease

    Gastroenterology, Vol. 146, Núm. Suppl. 1, pp. 247

2012

  1. Maximizing the effect of biologics in inflammatory bowel disease

    Minerva Gastroenterologica e Dietologica, Vol. 58, Núm. 2, pp. 101-122

  2. Tu1909 An Exome-Wide Genotyping Analysis for the Identification of Candidate Genes Associated With the Response to the Thiopurine Therapy in Inflammatory Bowel Disease Patients

    Gastroenterology, Vol. 142, Núm. 5, pp. S-875

2011

  1. New Genetic Associations Detected in an Exome-Wide Association Study for Toxicity Related to Thiopurine Treatments in Inflammatory Bowel Disease

    Gastroenterology, Vol. 140, Núm. 5, pp. S-271

2009

  1. M1130 Influence of Environmental Factors in the Severity of Inflammatory Bowel Disease

    Gastroenterology, Vol. 136, Núm. 5, pp. A-356

  2. M1161 Extraintestinal Manifestations in Inflammatory Bowel Disease. Are They Associated with More Severe Disease?

    Gastroenterology, Vol. 136, Núm. 5, pp. A-363

2008

  1. Differences in severity of IBD in patients from coastal/non coastal towns

    Gastroenterology, Vol. 134 Supp.1, Núm. 4, pp. A505